STAT

“Statistical Significance” and Statistical Reporting: Moving Beyond Binary

Null hypothesis significance testing (NHST) is the default approach to statistical analysis and reporting in marketing and the biomedical and social sciences more broadly. Despite its default role, NHST has long been criticized by both statisticians and applied researchers, including those within marketing. Therefore, the authors propose a major transition in statistical analysis and reporting. Specifically, they propose moving beyond binary: abandoning NHST as the default approach to statistical analysis and reporting. To facilitate this, they briefly review some of the principal problems associated with NHST. They next discuss some principles that they believe should underlie statistical analysis and reporting. They then use these principles to motivate some guidelines for statistical analysis and reporting. They next provide some examples that illustrate statistical analysis and reporting that adheres to their principles and guidelines. They conclude with a brief discussion.

AI linked to explosion of low-quality biomedical research papers

Analysis flags hundreds of studies that seem to follow a template, reporting correlations between complex health conditions and single variables based on publicly available data sets.

US Domestic Policy Dashboard - Impact Counter | Impact Counter

Explore US domestic policies and their impact on public health across all branches of government.

Fact Sheet 3: ME/CFS: Information for Medical Professionals

Fact Sheet 3: ME/CFS: Information for Medical Professionals Published December 2025 Link to pdf: ME/CFS: Information for Medical Professionals.pdf Discussion thread: Fact sheet #3: Information...

Avoidable mortality, risk factors and policies for tackling noncommunicable diseases – leveraging data for impact: monitoring commitments in the WHO European Region ahead of the Fourth United Nations High-Level Meeting

The report notes that, in order to tackle NCDs and address the commercial, social, environmental and digital determinants of health, there is a need for accelerated multisectoral whole-of-government and whole-of-society action, integrated policies, enhanced preventive measures and strengthened health systems.

Meta’s New AI Asked for My Raw Health Data—and Gave Me Terrible Advice

Meta’s Muse Spark model offers to analyze users’ health data, including lab results. Beyond the obvious privacy risks, it’s not a capable stand-in for a real doctor.

Improving and Expanding Estimates of the Global Burden of Disease Due to Environmental Health Risk Factors

Abstract Background: The Global Burden of Disease (GBD) study, coordinated by the Institute for Health Metrics and Evaluation (IHME), produces influential, data-driven estimates of the burden of disease and premature death due to major risk factors. Expanded quantification of disease due to environmental health (EH) risk factors, including climate change, will enhance accuracy of GBD estimates, which will contribute to developing cost-effective policies that promote prevention and achieving Sustainable Development Goals. Objectives: We review key aspects of the GBD for the EH community and introduce the Global Burden of Disease–Pollution and Health Initiative (GBD-PHI), which aims to work with IHME and the GBD study to improve estimates of disease burden attributable to EH risk factors and to develop an innovative approach to estimating climate-related disease burden—both current and projected. Methods: We discuss strategies for improving GBD quantification of specific EH risk factors, including air pollution, lead, and climate change. We highlight key methodological challenges, including new EH risk factors, notably evidence rating and global exposure assessment. Discussion: A number of issues present challenges to the scope and accuracy of current GBD estimates for EH risk factors. For air pollution, minimal data exist on the exposure–risk relationships associated with high levels of pollution; epidemiological studies in high pollution regions should be a research priority. For lead, the GBD’s current methods do not fully account for lead’s impact on neurodevelopment; innovative methods to account for subclinical effects are needed. Decisions on inclusion of additional EH risk–outcome pairs need to be guided by findings of systematic reviews, the size of exposed populations, feasibility of global exposure estimates, and predicted trends in exposures and diseases. Neurotoxicants, endocrine-disrupting chemicals, and climate-related factors should be high priorities for incorporation into upcoming iterations of the GBD study. Enhancing the scope and methods will improve the GBD’s estimates and better guide prevention policy. https://doi.org/10.1289/EHP5496

Chris Beiser on Twitter / X

it'd be interesting to quantify the rate at which unaffiliated reddit users have improved on the state of the art for treatment protocols for diseases. my guess is that for 75% of diseases, they're responsible for a greater QoL increase than pharmaceutical companies over 10 years— Chris Beiser (@ctbeiser) June 7, 2021

Statcounter Global Stats - Browser, OS, Search Engine including Mobile Usage Share

Tracks the Usage Share of Search Engines, Browsers and Operating Systems including Mobile from over 3 billion monthly page views.

9/11 Health

For over two decades the Registry researchers have been tracking health trends, investigating emerging health conditions, and identifying gaps in care among people affected by 9/11.

Bluesky Health Dashboard

Real-time health metrics for Bluesky

Claim denial rates from health insurers have been declining (maybe) - Kevin Drum

I'll have our last ACS chart later, but in the meantime I happened to run across some actual data about health insurer claim denial rates, the topic du jour since UnitedHealthcare CEO Brian Thompson was gunned down in broad daylight, allegedly in part because of his company's astronomical denial rate. These figures come from ACA transparency data and is limited…

The FDA Sentinel Real World Evidence Data Enterprise ( RWE ‐ DE )

Purpose The US Food and Drug Administration's Sentinel Innovation Center aimed to establish a query-ready, quality-checked distributed data network containing electronic health records (EHRs) linked...

The FDA Sentinel Real World Evidence Data Enterprise ( RWE ‐ DE )

Purpose The US Food and Drug Administration's Sentinel Innovation Center aimed to establish a query-ready, quality-checked distributed data network containing electronic health records (EHRs) linked...

How Health Disparities Develop over the Lifecycle

In the Netherlands, there are striking socioeconomic differences in mortality among older adults, with a 4.4 percentage point (67 percent) higher five-year mortality rate for 70-year-old individuals with below-median income than for those with above-median income. To better understand the role of chronic disease in these health disparities, Kaveh Danesh, Jonathan T. Kolstad, William D. Parker, and Johannes Spinnewijn develop an index of chronic disease burden in The Chronic Disease Index: Analyzing Health Inequalities over the Lifecycle (NBER Working Paper 32577). This index is a measure of health status that can be measured earlier in life and shows how chronic health evolves with age and differs across income groups.